The ability of the molecular subtypes to predict benefit from CDK4/6 inhibitors in breast cancer has been evaluated in samples from the PALOMA-216, the NeoPalAna17, and the MONALEESA-2,-3, and -718 studies. The gene discussed is CDK4; the disease is breast carcinoma.